Verastem to Present Data at the 2014 American Society of Hematology Annual Meeting

In total, five abstracts describing new preclinical data relating to the Company's ongoing research and development programs will be presented. Two of Verastem's drug candidates, VS-6063 and VS-4718, target cancer stem cells through potent inhibition of focal adhesion kinase .

http://ift.tt/1z8u4JF